Mahana Therapeutics, developer of prescription digital therapeutics designed to empower sufferers with power circumstances to dwell fuller lives, has signed an settlement with the Shopper Well being division of Bayer, which can see its new digital therapeutics commercialised.
The partnership will carry collectively the experience Mahana has in digital therapeutic improvement with Bayer’s intention to ship merchandise to assist folks take higher management of their very own well being by means of using digital options.
Earlier this 12 months Bayer introduced the launch of a brand new enterprise unit. The Shopper Well being division is targeted on bringing new digitally-enabled precision well being merchandise to market. The division is prioritising the event of merchandise that may allow folks to make use of digital options to take management of their well being, and facilitate their skill to make knowledgeable decisions primarily based on private insights and novel supply mechanisms.
David Evendon-Challis, head of R&D and chief scientific officer for the Shopper Well being division of Bayer, stated: “Digital therapeutics are an ideal addition to our portfolio of care and faucet into new tech-savvy shoppers in search of drug-free remedies in addition to assist remove gaps in care provision. We’re excited to accomplice with Mahana Therapeutics and enter the sector of digital therapeutics in client well being.”
The primary product from Mahana Therapeutics was Mahana IBS which supplies cognitive remedy to adults with the situation. The product was the primary digital therapeutic to obtain FDA clearance for the remedy of IBS.
Simon Levy, CEO of Mahana, stated: “This historic partnership is among the many first main investments ever made by a worldwide life sciences firm into the rising market for digital therapeutics.
“By this settlement, we will additional increase the supply of our revolutionary prescription digital therapeutics for sufferers and their caregivers all over the world who search efficient remedy for power circumstances.”